Prescription of DPP-4 inhibitors, which used to drive the diabetes treatment market, are on the decline. In just a single year, the market size of DPP-4 inhibitors decreased 4%, and this is the third consecutive quarter the market saw a decline since Q4 last year.

Also, multinational companies and domestic companies have seen opposite results in the sales performance of their products. While prescriptions of all DPP-4 inhibitors from multinational companies fell, most products from domestic companies continued to make growth.

◆Is the party over for DPP-4 inhibitors?... market decreased 4% in one year

According to the pharmaceutical market research institution UBIST on t